Depression is both overdiagnosed and underdiagnosed, depending on who you’re looking at and where the diagnosis happens. In some settings, particularly primary care, people with mild or temporary distress receive a depression label they may not warrant. In other populations, serious depression goes unrecognized for years. The real picture is messier than a simple yes or no.
What the Diagnosis Actually Requires
Major depressive disorder has a specific clinical threshold. The DSM-5 requires at least five symptoms present for two weeks or longer, and at least one of those symptoms must be persistent depressed mood or a loss of interest or pleasure in activities. The remaining symptoms include changes in appetite or weight, sleep disruption, physical restlessness or slowing, fatigue, difficulty concentrating, feelings of worthlessness or excessive guilt, and thoughts of suicide. These symptoms also need to cause meaningful impairment in daily life.
That threshold matters because sadness, grief, and temporary distress are normal human experiences. Feeling low after a job loss or breakup doesn’t automatically qualify. The line between “going through something hard” and “clinical depression” depends on symptom count, duration, and how much those symptoms disrupt your ability to function. In practice, though, that line gets blurry fast, especially when a doctor has 15 minutes to evaluate you.
How Often Primary Care Gets It Wrong
Most depression diagnoses happen in primary care, not in a psychiatrist’s office. And primary care physicians, working without structured diagnostic tools, get it right about half the time. A meta-analysis of 41 studies found that general practitioners’ unassisted depression diagnoses matched structured clinical interviews in only 47% of cases. Their sensitivity (correctly identifying people who are depressed) averaged around 50%, while their specificity (correctly identifying people who aren’t depressed) was about 81%.
That 50% sensitivity means roughly half of genuinely depressed patients walk out without a diagnosis. The 81% specificity means about one in five people labeled as depressed may not actually meet the full criteria. Both errors matter. The system simultaneously catches too many people who don’t have clinical depression and misses too many who do. This isn’t a failure of individual doctors so much as a structural problem: depression diagnosis relies entirely on subjective symptom reports, clinical judgment, and time-pressured conversations. No blood test, brain scan, or biomarker has been validated for routine clinical use as of 2025.
The Bereavement Exclusion Debate
One of the most controversial changes in modern psychiatry was the removal of the bereavement exclusion when the DSM-5 was published in 2013. Under the previous edition, a person grieving the death of a loved one could not be diagnosed with major depression during the first two months of bereavement, unless their symptoms were extreme (psychosis, suicidal behavior, severe functional impairment). The DSM-5 eliminated that carve-out entirely.
Critics argued this would medicalize normal grief, turning a universal human experience into a psychiatric disorder. Defenders pointed out that the exclusion was inconsistent: losing a spouse could shield you from a depression diagnosis, but losing a job or receiving a terminal diagnosis could not. They also noted the practical impact was small. In a large national survey, only 0.5% of subjects fell into the “bereavement-excluded depression” category. Still, the symbolic weight of the change fueled broader concerns about diagnostic creep.
How Drug Marketing Shapes Diagnosis
Pharmaceutical advertising plays a documented role in expanding who gets diagnosed and treated. A randomized controlled trial using actors trained to portray either major depression or a milder adjustment disorder found striking results. When the actor made no medication request, physicians prescribed antidepressants 31% of the time for major depression and just 10% of the time for adjustment disorder. When the actor specifically requested a brand-name antidepressant they’d seen advertised on television, prescribing jumped to 53% for major depression and 55% for adjustment disorder.
That last number is the telling one. Adjustment disorder is a temporary stress response, not clinical depression, yet more than half of patients portraying it received antidepressants simply because they asked for a specific brand. Physicians were also significantly more likely to even record a depression diagnosis when patients requested medication: 88% versus 65% in the major depression group, and 50% versus 18% in the adjustment disorder group. The study’s authors concluded that direct-to-consumer advertising may stimulate prescribing more for questionable indications than for clear ones.
Antidepressants Without a Diagnosis
A large study across ten health systems found that 39% of people filling antidepressant prescriptions had received no mental health diagnosis at all during that year. Some of this is explained by legitimate off-label uses: certain antidepressants are commonly prescribed for chronic pain, insomnia, or smoking cessation. After excluding the drugs most often used for non-psychiatric reasons, the proportion with no mental health diagnosis dropped to 27%. That still means roughly one in four people taking antidepressants that are primarily prescribed for mood disorders had no documented psychiatric condition.
This doesn’t necessarily mean those patients don’t have depression. Some may have been diagnosed in a previous year. Others may have symptoms their doctors chose to treat without formally coding a diagnosis. But the gap between prescriptions and documented diagnoses raises legitimate questions about how carefully the clinical criteria are being applied before treatment begins.
Who Gets Missed
While overdiagnosis gets the headlines, underdiagnosis remains a serious problem in specific populations. Black, Latino, and Asian Americans all have lower rates of diagnosed depression than white Americans, but the data suggest this reflects detection failures rather than genuinely lower rates. Black and Latino adults who do receive a depression diagnosis have higher rates of persistent and severe symptoms compared to white adults, a pattern consistent with people being diagnosed only once their condition has progressed to a point that’s impossible to miss.
Part of the gap comes from how depression presents differently across cultural and demographic lines. Some groups are more likely to express depression through physical symptoms, irritability, or agitation rather than the “classic” sadness and withdrawal that screening tools are built to detect. Research has found that Black Americans are more likely to be misdiagnosed with psychotic-spectrum disorders when they actually have mood disorders, suggesting racial bias compounds the diagnostic inaccuracy. Standard interview tools may not capture the burden of depression equally across racial and ethnic groups.
Men are another commonly underdiagnosed group. Depression in men more often manifests as anger, risk-taking, or substance use rather than tearfulness or expressed hopelessness, and these presentations frequently go unrecognized as depressive symptoms.
Rising Rates: Real or Artificial?
Global data shows depression prevalence among 10 to 29 year olds increased about 19% between 1990 and 2021, rising from roughly 12,000 to 14,300 cases per 100,000 people. But interpreting that number is complicated. In wealthier countries with better healthcare access, prevalence has risen substantially, while in lower-income regions it has stayed flat or declined. Researchers note this pattern likely reflects increased recognition and willingness to report depression in high-income countries, not necessarily a true explosion in the underlying condition.
That said, dismissing the entire increase as an artifact of better detection is probably wrong too. The age group showing the steepest rise is 10 to 14 year olds, suggesting earlier onset of depressive disorders. Social media use, academic pressure, economic uncertainty, and the aftereffects of the COVID-19 pandemic all represent plausible contributors to a genuine increase, particularly among young people. The most honest reading of the data is that both factors are at work: more real depression and more detection of milder cases that might previously have gone unlabeled.
Why It Matters Either Way
Overdiagnosis carries real costs. People given a depression label they don’t need may take medications with side effects for years, internalize an identity as “mentally ill” that doesn’t serve them, or miss the actual source of their distress (a bad relationship, financial stress, grief that needs time, not treatment). It also dilutes clinical resources, making it harder for people with severe depression to access care.
Underdiagnosis is equally damaging. Untreated major depression worsens over time, increases the risk of suicide, and damages physical health, relationships, and the ability to work. For every person casually handed an antidepressant they may not need, there is someone suffering in silence because their symptoms don’t match the textbook presentation, or because their doctor didn’t ask the right questions, or because cultural stigma kept them from raising it at all.
The problem isn’t that doctors diagnose too much or too little. It’s that depression diagnosis still relies on brief, subjective conversations with no objective confirmation, happening in a system where time is short, pharmaceutical marketing is loud, and the tools work better for some people than others.